Tiziana Life Sciences Secures Up to $10 Million in Offering
Tiziana Life Sciences, Ltd. (NASDAQ: TLSA), a prominent biotechnology firm known for its innovative immunomodulation therapies, has recently made significant strides by entering into a securities purchase agreement. This agreement involves the sale of 5,263,158 common shares at a price of $0.95 each, leading to expected gross proceeds of approximately $5 million.
Details of the Offering
The offering is set to close on a specific date, pending the usual closing conditions. In addition to the initial offering, there is also an option provided to investors, allowing them to purchase an additional 5,263,158 common shares at the same price within 75 days post-closing. This option could potentially generate an additional $5 million, reflecting the company's confidence in its future prospects.
Utilization of Proceeds
The net proceeds from this offering are aimed at advancing Tiziana's Phase 2a clinical trial. This trial will focus on the intranasal administration of foralumab, targeted at patients with non-active secondary progressive multiple sclerosis. Additionally, these funds are intended to expedite the clinical development of foralumab for Alzheimer's disease, along with supporting the exploration of other indications and general corporate needs.
About Tiziana Life Sciences
As a clinical-stage biopharmaceutical entity, Tiziana Life Sciences is dedicated to the development of groundbreaking therapies. They are particularly recognized for their innovative methods of drug delivery that aim to enhance both the efficacy and safety of treatment options compared to traditional intravenous routes. Their flagship candidate, intranasal foralumab, has showcased a promising safety profile and encouraging clinical responses in earlier trials.
A Unique Approach to Immunotherapy
Tiziana's pioneering approach involves the use of nasal administration which has the potential to revolutionize how patients receive immunotherapy. This method not only improves the ease of administration but also aims to enhance treatment outcomes. The company holds patents for this technology and is actively pursuing additional applications within this space.
Contact Information
For inquiries, Tiziana Life Sciences can be reached at the following contact:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@tizianalifesciences.com
Frequently Asked Questions
What is the purpose of Tiziana's recent offering?
The recent offering aims to raise funds primarily for clinical trials and the development of their lead therapeutic candidate, intranasal foralumab.
How much money is Tiziana hoping to raise?
Tiziana is looking to raise approximately $10 million through this offering, with $5 million initially and an option for an additional $5 million.
What clinical trial is Tiziana pursuing?
Tiziana is advancing a Phase 2a clinical trial focused on the use of intranasal foralumab for treating patients with non-active secondary progressive multiple sclerosis.
What are the benefits of Tiziana's drug delivery method?
The nasal delivery method is designed to improve the efficacy, safety, and tolerability of immunotherapy compared to traditional intravenous methods.
Who can I contact for more information about Tiziana Life Sciences?
You can reach out to Paul Spencer at Tiziana Life Sciences through the provided contact information for further inquiries.